A 62-year-old woman with Stage 4 CKD (eGFR 22 mL/min/1.73m²), diabetes mellitus type 2, and hypertension is found to have serum phosphate of 5.2 mg/dL and serum calcium of 8.1 mg/dL. She is not yet on dialysis. What is the drug of choice to control her hyperphosphatemia?

Explanation

## Phosphate Binder Selection in Stage 4 CKD **Key Point:** Sevelamer is the preferred first-line phosphate binder in Stage 4 CKD because it is non-absorbable, does not increase serum calcium (avoiding hypercalcemia and vascular calcification), and reduces LDL cholesterol as a bonus. **High-Yield:** Phosphate binder choice depends on: 1. **Serum calcium status** (low, normal, or high) 2. **Cardiovascular risk** (vascular calcification risk) 3. **Stage of CKD** (pre-dialysis vs. dialysis) In this patient: - Serum calcium is LOW (8.1 mg/dL; normal 8.5–10.5) - Serum phosphate is HIGH (5.2 mg/dL; target <4.5 in Stage 4) - She is pre-dialysis (eGFR 22) **Clinical Pearl:** Sevelamer is a non-calcium, non-metal phosphate binder that: - Binds phosphate in the GI tract without systemic absorption - Does NOT increase serum calcium (crucial when calcium is already low) - Reduces LDL cholesterol by ~30% - Reduces vascular calcification risk - Available as sevelamer HCl or sevelamer carbonate **Mnemonic:** **SEV-EM** = **S**evelamer is **E**xcellent for **V**ascular calcification prevention and **EM**phasizes non-calcium binding. ### Phosphate Binder Comparison Table | Binder | Type | Mechanism | Serum Ca Effect | Vascular Calcification | Use in Stage 4 CKD | |---|---|---|---|---|---| | **Sevelamer** | Non-metal | Binds PO₄ in GI tract | No ↑ | Reduced | **First-line** | | Calcium acetate | Calcium-based | Binds PO₄; absorbed Ca | ↑↑ | Increased risk | Avoid if Ca low | | Lanthanum carbonate | Rare earth metal | Binds PO₄; minimal absorption | No ↑ | Reduced | Alternative if sevelamer intolerant | | Aluminum hydroxide | Aluminum-based | Binds PO₄; absorbed Al | No ↑ | Neutral | **Avoid** (Al toxicity risk) | **Warning:** Calcium-based binders (calcium acetate, calcium carbonate) are contraindicated when serum calcium is low or normal, as they risk hypercalcemia and accelerate vascular and soft-tissue calcification. Aluminum hydroxide is obsolete due to aluminum accumulation toxicity (bone disease, encephalopathy).